US News Coronavirus. London asks its health regulator to review AstraZeneca

08:45  27 november  2020
08:45  27 november  2020 Source:   ouest-france.fr

Covid-19: the United States hopes to vaccinate 20 million people by the end of the year

 Covid-19: the United States hopes to vaccinate 20 million people by the end of the year The prospect of first vaccinations against Covid-19 in the United States by the end of the year is materializes: after Pfizer / BioNTech last week, the American biotechnology company Moderna announced Monday that its vaccine was 94.5% effective. The two vaccines could be authorized by the United States Medicines Agency (FDA) in the first half of December, said Monday Moncef Slaoui, scientific manager of Operation Warp Speed, set up by President Donald Trump to vaccinate the American population.

The British government formally asked the country's medicine regulator on Friday to assess Oxford AstraZeneca expects 4 million doses of its vaccine to be available in the country by the end of next Read more: Coronavirus : How Germany is preparing for a vaccination drive. The regulator said it

AstraZeneca might eventually find itself in need of answering key questions about its would-be jab as it rushed to get regulators ’ approval for it. 1.Half dose or full dose? The company’s assessment of its vaccine effectiveness in fact comes as an estimated average for two slightly different tests.

Le vaccin d'AstraZeneca présente l'avantage d'utiliser une technologie plus traditionnelle qui le rend moins coûteux et plus facile à stocker. vaccine © AFP PHOTO / UNIVERSITY OF OXFORD / John Cairns AstraZeneca vaccine has the advantage of using more traditional technology that makes it cheaper and more easy to store.

London has asked the Medicines Regulatory Authority (MHRA) to review the vaccine against the new coronavirus developed by the British laboratory AstraZeneca for commercialization.

The British government announced on Friday that it had asked the Medicines Health Regulatory Authority (MHRA) to review the vaccine against the novel coronavirus developed by the British laboratory AstraZeneca and the University of Oxford, with a view to its commercialization.

Coronavirus: how to explain the low number of daily cases in Paris

 Coronavirus: how to explain the low number of daily cases in Paris © Ludovic MARIN / AFP As the second wave sweeps over France, Paris has few new daily cases compared to its population. The department is even the 14th department where there are fewer cases. An exception when the virus is developing rapidly in metropolitan areas. The second wave is "massive, deadly and straining caregivers and our entire health system". This is how the Director General of Health, Jérôme Salomon, described the French health situation on Tuesday evening.

AstraZeneca has not yet tested its half-strength dose in the US either. Dermot Hickey, left, and Phillip Vega ask a pedestrian in New York to take their picture on a thinly trafficked Fifth Photos: The novel coronavirus outbreak. Health -care workers and union members demonstrate during a Bastille

LONDON — Pharmaceutical giant AstraZeneca will resume its coronavirus vaccine trial in the U.K "Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the U.K An independent review process and a British medical regulator has now recommended "that trials in

"We have officially asked the health regulator to evaluate the Oxford / AstraZeneca vaccine and determine whether it meets rigorous safety standards," , Health Minister Matt Hancock said in a statement.

"Important step towards deployment"

If approved, this will be an "Important step towards the deployment of a vaccine as soon as possible" , he added.

United Kingdom , the most bereaved country in Europe by the epidemic with more than 57,000 dead, is also “the first country in the world to have signed an agreement with AstraZeneca and the University of Oxford, guaranteeing him access to 100 million doses ”, specifies the Ministry of Health.

If the vaccine is authorized, 4 million doses will be delivered to the UK before the end of the year, followed by another 40 million before the end of March 2021.

Coronavirus: The peak of the second wave has undoubtedly been crossed in France

 Coronavirus: The peak of the second wave has undoubtedly been crossed in France The number of contaminations is falling sharply, the number of hospitalizations is also beginning to decline © UGO AMEZ / SIPA A naso- RT-PCR test pharyngeal performed in Bordeaux.

Phase three trials for AstraZeneca 's coronavirus vaccine have resumed in the U.K. after they were halted earlier AstraZeneca said it received confirmation from the United Kingdom's Medicines Health Regulatory 6 so that independent committees and internal regulators could review the safety data.

AstraZeneca - the company collaborating with Oxford University on a coronavirus vaccine - is set to run an extra trial of the jab. © Reuters AstraZeneca says the new study will be international. It is likely to be an "international study, but this one could be faster because we know the efficacy is high

On Thursday, the CEO of AstraZeneca announced that the vaccine would be submitted to "an additional study" after criticism of its first results, without this delaying, according to him, its approval by European and British regulators.

The vaccine is said to be 70% effective

According to interim results from large-scale clinical trials published on Monday, the vaccine is on average 70% effective. However, behind this average lie large differences between two different protocols: the efficacy is 90% for the volunteers who first received a half-dose, then a full dose a month later, but only 62% for another group, which was however more vaccinated, with two complete doses.

While the injection of half a dose was originally due to an error, which explains why only 3000 patients followed this protocol, the results seem to show that this first regimen results in a better immune response.

"Now that we have found what appears to be better efficacy, we need to validate it, so do an additional study" , Pascal Soriot said in an interview with Bloomberg agency.

For the time being, less convincing than that of Pfizer / BioNTech or Moderna, AstraZeneca's vaccine has the advantage of using more traditional technology which makes it less expensive and easier to store.

The previous week, the British government had already asked its health regulator to examine the Pfizer / BioNTech vaccine, of which it is expected to order 40 million doses.

In the United States, a high-risk Thanksgiving, Europe eases restrictions .
© Provided by Le Point Virtual parade and calls for limited gatherings, Americans celebrate Thursday a Thanksgiving tarnished by the new embrace of the epidemic in the country, while the Europe slightly relaxed its restrictions despite a caveat: the AstraZeneca / Oxford University vaccine requires "further study". Pandemic Obliges, the famous Thanksgiving parade with giant balloons that usually brings millions of people to the streets of New York, was held without an audience.

usr: 0
This is interesting!